- Stockholders' equity significantly surpasses the $2.5 million minimum required by Nasdaq - Company is to seek Nasdaq's formal confirmation of compliance with equity requirements under the exchange's Rule 5550(b)(1). - Company will submit a request to the SEC to withdraw Form S-1 Boston (May 6, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that its stockholders' e ...

Boston (May 2, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced the early discontinuation of its Phase 2 clinical trial of stenoparib, a novel PARP inhibitor, for the treatment of advanced recurrent ovarian cancer. The patients enrolled in the trial had been pre-screened by Allarity's unique Drug Response predictor (DRP®) companion diagnostic (CDx) in order to treat o ...

Boston (April 29, 2024) — Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that on April 27, 2024, it received formal notice from The Nasdaq Stock Market, LLC's Office of General Counsel ("Nasdaq"). This notice confirmed that the Company has regained compliance with the minimum bid price requirement as set forth in Nasdaq's Listing Rule 5550(a)(2) (the "Bid Price Rule"). Na ...

公司概况 - Allarity Therapeutics, Inc.（NASDAQ:ALLR）是一家专注于开发个性化癌症治疗的临床阶段制药公司[6] 股票情况 - 公司最近实施了1比20的股票逆向拆分，旨在恢复出价合规性[4] 财务调整 - Allarity正在积极努力调整其财务结构，包括持续降低运营支出和与关键利益相关者进行谈判[4]

Allarity Therapeutics (NASDAQ:ALLR) stock is heading higher on Friday alongside heavy pre-market trading.Investors will note that this movement comes after the company announced a prospectus supplement. This alters the maximum aggregate offering price of shares sold through prospectus from $1,350,000 to $2,350,000.Allarity Therapeutics notes that it currently has 828,580 shares outstanding with a value of $7,092,593. The amendment mentions that the company has sold $1,348,908 worth of its shares and is elig ...

Boston (April 4, 2024) — Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced the implementation of a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 9:30 a.m. Eastern Time on April 9, 2024. The Company's common stock will begin trading on a split-adjusted basis wh ...

Leadership Changes Led by Appointment of Co-Founder Thomas Jensen as Interim CEO and Jeremy Graff, Ph.D., former Eli Lilly Executive, as Executive AdvisorReduced Net Loss from Operations by 50% and Reduced Net Loss by 26%Announced Data in December 2023 from Advanced Ovarian Cancer Phase 2 Stenoparib Study Showing Significant Clinical Benefit Boston (March 8, 2024) — Allarity Therapeutics, Inc. ("Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer tre ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 87-2147982 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to_________ Commission file num ...

研发费用 - 2023年全年研发费用为710.3万美元，相比2022年的690万美元略有增加[9] 运营支出 - 2023年全年总体运营支出为1712.9万美元，较2022年的3446.3万美元减少了50%[15] 净亏损 - 2023年全年净亏损为1190.1万美元，较2022年的1610.8万美元减少了26%[15] 公司资产 - 2023年12月31日，Allarity Therapeutics, Inc.的总资产为11,862千美元，较2022年12月31日的14,544千美元有所下降[16] 公司财务状况 - 公司的现金为166千美元，其他流动资产为209千美元，预付费用为781千美元，税收抵免为815千美元[16] - 公司的总负债为14,613千美元，较上一年的12,654千美元有所增加[16]

公司介绍 - Allarity Therapeutics, Inc.是一家致力于开发个性化癌症治疗的临床阶段制药公司[5] 首席执行官介绍 - 公司的首席执行官Thomas Jensen将在Biomarkers 2024上介绍公司开发的药物特异性药物反应预测器（DRP®）伴随诊断（CDx）平台的创新工作[2] 临床研究成果 - DRP®伴随诊断平台已在37项临床研究中证明其能够对癌症患者的药物治疗临床结果进行统计显著预测[4]